{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"54.9","upperLimit":"90.6","value":"76"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Clinical benefit response rate is calculated as the percent of evaluable patients that have confirmed stringent complete remission (sCR), complete remission (CR), very good partial remission (VGPR), partial remission (PR), minimal response (MR) or stable disease (SD) per modified IMWG criteria. The exact 95% confidence intervals are calculated for the estimate.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 4mg ixazomib citrate (MLN9708) orally on days 1, 8, and 15; dexamethasone orally on days 1, 8, 15, and 22; and pomalidomide orally on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Dose Level #2 (4mg MLN9708)"}],"paramType":"NUMBER","populationDescription":"Patients received 4 mg MLN9708, 4mg pomalidomide, and 40 mg dexamethasone (RP2D).","reportingStatus":"POSTED","timeFrame":"From the initial treatment up to 24 months","title":"Clinical Benefit Response Rate at the Recommended Phase II Dose (RP2D)","type":"SECONDARY","unitOfMeasure":"Percentage of Participants (%)"}